CLOs on the Move

Standard Bio

www.standardbio.com

 
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.standardbio.com
  • 2 Tower Place Suite 2000
    South San Francisco, CA USA 94080
  • Phone: 650.266.6000

Executives

Name Title Contact Details
Michael Bastian
Chief Intellectual Property Counsel Profile
Agnieszka Gallagher
Chief Legal Officer Profile
Nicholas Khadder
SVP, General Counsel and Corporate Secretary Profile

Similar Companies

Symic Biomedical

Symic is developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease. While it is clear that cells play an important role in tissue inflammation and regeneration, it is also known that the extracellular matrix (ECM) plays an equally critical role in maintaining healthy tissue. The ECM is the non-cellular component of the body’s tissues, and proteoglycans are important structural and functional macromolecules native to the ECM that are known to protect against tissue degradation and promote healing during illness or injury. Recognizing the importance of proteoglycans in many acute and chronic disease states, Symic developed a library of proprietary, ECM-specific compounds that mimic the protective effect of natural proteoglycans. For controlled injuries (e.g. incisions, balloon angioplasty), Symic’s ECM-specific compounds allow for local application, enhancing their ability to attenuate inflammation and reduce scarring only at the site of injury. In disease states known for chronic inflammation involving the ECM (e.g. cartilage in osteoarthritis), Symic’s technology can disrupt the cycle of degradation-inflammation by directly targeting and protecting the injured ECM. The ECM plays a critical role in many acute and chronic disease states, many of which have limited or no effective therapeutic options. Symic plans to advance its compounds in a variety of therapeutic areas with unmet clinical needs.

Guava Technologies

Guava Technologies, Inc. is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Bioworld

Bioworld is a Dublin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ONL Therapeutics

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.​

Pharmadule

Pharmadule is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.